News | May 08, 2014

Early-stage breast cancer treatment enables more women to opt for partial breast radiation


May 8, 2014 — Cianna Medical announced the results of a trial examining the long-term side effects of strut-based brachytherapy for early-stage breast cancer. According to researchers, treatment with SAVI breast brachytherapy resulted in very low rates of late toxicities, even in patients with minimal space between the tumor cavity and skin.

SAVI is a strut-based device that delivers a form of accelerated partial breast irradiation (APBI) known as breast brachytherapy, a five-day course of targeted radiation for early-stage breast cancer. With more than 10 years of clinical evidence showing excellent outcomes in efficacy and safety, breast brachytherapy is proven to be an appropriate treatment for early-stage breast cancer.

“The strut-based, open architecture design of SAVI allows physicians to safely deliver radiation, even in close proximity to the skin or chest wall, which offers a significant advantage over other brachytherapy techniques,” said study co-author Emily Penman, M.D., medical director of the Helen F. Graham Cancer Center at Christiana Care Health System, Newark, Del. “Our study confirms that strut-based brachytherapy allows us to treat any woman who is otherwise eligible for partial breast radiation with minimal risk of long-term toxicities.”

The study was presented at the annual meeting of the American Society of Breast Surgeons in Las Vegas. It examines 468 patients (469 breasts) treated with strut-based brachytherapy from 2007 to 2011. Of that group, 113 patients (114 breasts) had skin bridges of 5 mm or less. Late cutaneous toxicities (hyperpigmentation, erythema and telangiectasias) were analyzed for the entire cohort and those patients with small skin bridges.

Toxicity post-treatment for the entire group (with a median follow up of 27 months) was low: hyperpigmentation – 0.2 percent; erythema – 1.5 percent; and telangiectasias – 1.3 percent. Toxicities were similarly low for the ? 5 mm skin bridge group (which had a median follow up of 33 months): hyperpigmentation – 0.0 percent; erythema – 2.6 percent; and telangiectasias – 1.8 percent.

Data came from the SAVI Collaborative Research Group (SCRG), which studies the long-term outcomes of women treated with strut-based brachytherapy. Additional data from the SCRG has shown excellent local control with strut-based brachytherapy, with a 2 percent recurrence rate at four-and-a-half years median follow-up.

“Strut-based breast brachytherapy is proving to be a safe and effective way to deliver partial breast radiation,” said lead author Jon Strasser, a radiation oncologist at the Helen F. Graham Cancer Center. “This is great news for our patients, who are thrilled to have access to a treatment that delivers highly targeted radiation in a much more convenient way.”

Strut-based brachytherapy is used as part of breast conservation therapy, which consists of a lumpectomy followed by radiation therapy. Traditionally, the radiation portion consisted of whole breast irradiation (WBI), which requires six to seven weeks of daily treatments. Breast brachytherapy delivers radiation to the area immediately surrounding the lumpectomy cavity, sparing healthy tissue from unnecessary radiation and enabling treatment to be completed in as little as five days. Patient eligibility for breast brachytherapy is based on a number of factors, including tumor size, type of cancer, age, margin status and lymph node involvement.

For more information: www.ciannamedical.com

Related Content

360 Photos | Brachytherapy Systems

This is a 360 degree view inside one of the brachytherapy treatment rooms at Northwestern Medicine's center in ...

Time October 28, 2021
arrow
News | Brachytherapy Systems

August 31, 2021 — iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy ...

Time August 31, 2021
arrow
News | Radiation Oncology

June 2, 2021 — A breast cancer therapy that requires just one shot of radiotherapy is as effective as traditional ...

Time June 02, 2021
arrow
News | Brachytherapy Systems, Women's Healthcare

May 19, 2021 — A new study finds that brachytherapy, a common procedure that delivers radiation directly to cancer cells ...

Time May 19, 2021
arrow
News | Brachytherapy Systems

October 26, 2020 — iCAD, Inc. announced the Company will showcase the expanded platform for the Xoft Axxent Electronic ...

Time October 26, 2020
arrow
News | Brachytherapy Systems, Women's Healthcare

September 8, 2020 — Advanced Radiation Therapy has completed the installation of the AccuBoost Digital platform at the ...

Time September 08, 2020
arrow
News | Brachytherapy Systems, Women's Healthcare

At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago, Advanced Radiation Therapy, makers of AccuBoost, announced the latest upgrades to the AccuBoost Digital platform. AccuBoost Digital leverages the Planmed Clarity digital mammography system to provide doctors with real-time image-guidance and targeting confidence in the delivery of accelerated partial breast irradiation (APBI) in patients opting for breast conserving therapy (BCT). These upgrades improve the treatment workflow, patient experience and user interface. By design, this non-invasive breast brachytherapy (NIBB) technique is 100 percent adaptive as each treatment fraction is assessed independently and is ideal for the challenges that APBI treatments can present.

Time October 23, 2019
arrow
Videos | Radiation Therapy

ITN Associate Editor Jeff Zagoudis speaks with Christy Kesslering, M.D., medical director of radiation oncology at the ...

Time February 21, 2019
arrow
News | Brachytherapy Systems, Women's Healthcare

Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent Electronic Brachytherapy (eBx) System were comparable to those seen in the TARGIT-A and ELIOT trials, according to new results. The results, published in the Annals of Surgical Oncology, came from a long-term study conducted at Hoag Memorial Hospital Presbyterian in Newport Beach, Calif.

Time January 07, 2019
arrow
News | Women's Health

Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to acquire Cianna Medical Inc., headquartered in Aliso Viejo, Calif. The deal structure includes an upfront payment of $135 million with potential earn-out payments of an additional $15 million for achievement of supply chain and scalability metrics, and up to an additional $50 million for achievement of sales milestones.

Time November 14, 2018
arrow
Subscribe Now